
- Tecfidera (multiple sclerosis): $4.2 billion, Biogen-Idec, dimethyl-fumarate
- Kadcyla (breast cancer): $2.9 billion, Genentech, antibody conjugate
- Breo Ellipta (COPD): $1.84 billion, Glaxo+Theravance, Steroid+beta2 agonist
- Pomalyst (multiple myeloma): $1.28 billion, Celgene, Thalidomide analogue
- Nesina (diabetes): $1.1 billion, Takeda, DPP4 inhibitor
If you enjoy my blog, follow VictrixCMC on LinkedIn, Facebook, and Twitter (@VictrixCMC)